- Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
-
Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Ahmed A
- KMID: 2560102
- Clin Mol Hepatol.
- 2024 Oct;30(4):982-986.
- doi: 10.3350/cmh.2024.0691
-
- CITED
-
- Close
- SHARE
-
- Close
- Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023
-
Kim D, Manikat R, Wijarnpreecha K, Cholankeril G, Ahmed A
- KMID: 2560084
- Clin Mol Hepatol.
- 2024 Oct;30(4):756-770.
- doi: 10.3350/cmh.2024.0318
Backgrounds/Aims: The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve. We estimated the sex- and race/ethnicity-based... -
- CITED
-
- Close
- SHARE
-
- Close
- Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
-
Crane H, Eslick GD, Gofton C, Shaikh A, Cholankeril G, Cheah M, Zhong JH, Svegliati-Baroni G, Vitale A, Kim BK, Ahn SH, Kim MN, Strasser SI, George J
- KMID: 2557394
- Clin Mol Hepatol.
- 2024 Jul;30(3):436-448.
- doi: 10.3350/cmh.2024.0109
Background/Aims: The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis... -
- CITED
-
- Close
- SHARE
-
- Close
